Avacta Group (DB:RTQ1) - Aandelenkoers, Nieuws & Analyse

RTQ1 Overzicht aandelen

Avacta Group Plc ontwikkelt geneesmiddelen tegen kanker en in-vitro diagnostica in het Verenigd Koninkrijk, Frankrijk, Noord-Amerika, Zuid-Korea, de rest van Europa en internationaal.

Over het bedrijf

RTQ1 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 14.32% per jaar groeien

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 0.4% per jaar dalen.

Heeft minder dan 1 jaar cash runway

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

+ 1 meer risico

Avacta Group Plc Concurrenten

2invest

XTRA:2INV

€59.2m

Heidelberg Pharma

XTRA:HPHA

€116.5m

Formycon

XTRA:FYB

€863.4m

Biotest

XTRA:BIO3

€1.3b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Avacta Group
Historische aandelenkoersen
Huidige aandelenkoers	UK£0.57
52 Week Hoogtepunt	UK£1.78
52 Week Laag	UK£0.41
Bèta	1.12
11 maand verandering	5.56%
3 maanden verandering	-22.45%
1 Jaar Verandering	-61.75%
33 jaar verandering	-54.03%
5 jaar verandering	n/a
Verandering sinds IPO	-63.81%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	RTQ1	DE Biotechs	DE Markt
7D	-8.8%	-3.1%	-1.0%
1Y	-61.7%	-15.2%	16.1%

Rendement versus industrie: RTQ1 presteerde slechter dan de German Biotechs -sector, die het afgelopen jaar een rendement van -15.2 % opleverde.

Rendement versus markt: RTQ1 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 16.1 % opleverde.

Prijsvolatiliteit

Is RTQ1's price volatile compared to industry and market?
RTQ1 volatility
RTQ1 Average Weekly Movement	16.6%
Biotechs Industry Average Movement	6.1%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van RTQ1 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 17% ) van RTQ1 is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2003	154	Chris Coughlin	www.avacta.com

Avacta Group Plc ontwikkelt geneesmiddelen tegen kanker en in-vitro diagnostica in het Verenigd Koninkrijk, Frankrijk, Noord-Amerika, Zuid-Korea, de rest van Europa en internationaal. Het bedrijf opereert via de segmenten Diagnostica en Therapeutica. Het bedrijf biedt zijn eigen Affimer- en pre|CISION-technologieplatforms aan, die worden gebruikt om een portfolio van gedifferentieerde therapeutische en diagnostische producten te leveren voor verschillende markten.

Avacta Group Plc Samenvatting

Hoe verhouden de winst en inkomsten van Avacta Group zich tot de beurswaarde?
RTQ1 fundamentele statistieken
Marktkapitalisatie	€231.59m
Inkomsten(TTM)	-€30.92m
Inkomsten(TTM)	€27.01m

8.6x

P/S-verhouding

-7.5x

Koers/Winstverhouding

Is RTQ1 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
RTQ1 resultatenrekening (TTM)
Inkomsten	UK£22.62m
Kosten van inkomsten	UK£13.10m
Brutowinst	UK£9.52m
Overige uitgaven	UK£35.40m
Inkomsten	-UK£25.89m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.071
Brutomarge	42.08%
Nettowinstmarge	-114.45%
Schuld/Eigen Vermogen Verhouding	49.8%

Hoe presteerde RTQ1 op de lange termijn?

Bekijk historische prestaties en vergelijking

RTQ1 Overzicht aandelen

Beloningen

Risicoanalyse

Avacta Group Plc Concurrenten

XTRA:2INV

€59.2m

XTRA:HPHA

€116.5m

XTRA:FYB

€863.4m

XTRA:BIO3

€1.3b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs At 2024 Eortc-Nci-Aacr Symposium

First half 2024 earnings released: UK£0.038 loss per share (vs UK£0.043 loss in 1H 2023)

New major risk - Financial position

Recent updates

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs At 2024 Eortc-Nci-Aacr Symposium

First half 2024 earnings released: UK£0.038 loss per share (vs UK£0.043 loss in 1H 2023)

New major risk - Financial position

Avacta Group plc Reports Updated Phase 1 Data of Ava6000 At the European Society for Medical Oncology Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

Avacta Group Plc to Report First Half, 2024 Results on Sep 30, 2024

Avacta Group plc Announces Board Changes

Avacta Group plc Announces Board Changes

Avacta Group Plc, Annual General Meeting, Jun 26, 2024

Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Full year 2023 earnings released: UK£0.091 loss per share (vs UK£0.15 loss in FY 2022)

New minor risk - Financial data availability

Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting

Avacta Group Plc Announces Update on AVA6000 Phase 1a Clinical Trial Progress

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has filed a Follow-on Equity Offering in the amount of AUD 20.560243 million.

Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer

Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division

Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study

First half 2023 earnings released: UK£0.043 loss per share (vs UK£0.036 loss in 1H 2022)

New major risk - Financial position

Avacta Group Plc Announces Management Changes

Avacta Group plc Announces Successful Completion of ALS-6000-101 Sixth Dose Escalation

Avacta Group Plc to Report First Half, 2023 Results on Sep 28, 2023

New major risk - Share price stability

New major risk - Share price stability

Avacta Announces Successful Completion of Fifth Dose Escalation in Ava6000 Phase 1 Clinical Study

Avacta Group plc Appoints Shaun Chilton to the Board as Non-Executive Director

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Avacta Group Plc, Annual General Meeting, Jun 28, 2023

Avacta Group plc acquired Coris Bioconcept SRL for £10.4 million.

Full year 2022 earnings released: UK£0.15 loss per share (vs UK£0.11 loss in FY 2021)

Avacta Group plc Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

High number of new and inexperienced directors

Avacta Group Plc (AIM:AVCT) conditionally agreed to acquire Launch Diagnostics Holdings Limited for £37 million.

First half 2022 earnings released: UK£0.036 loss per share (vs UK£0.041 loss in 1H 2021)

Avacta Group Plc to Report First Half, 2022 Results on Sep 29, 2022

Avacta Group plc Announces Phase I Study of AVA6000 Advances to Fourth Cohort

High number of new and inexperienced directors

Avacta Group Plc announced that it has received funding

Avacta Group Plc Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group Plc, Annual General Meeting, Jun 23, 2022

Avacta Group Plc Relocates its Therapeutics Division to New Headquarters at Scale Space, in Imperial College's White City Campus, London

Less than half of directors are independent

Full year 2021 earnings released: UK£0.11 loss per share (vs UK£0.084 loss in FY 2020)

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group plc Selects Second Pre|Cision™ Pro-Drug Candidate for Development

Avacta Group plc Provides Update on AffiDX SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant

Avacta Group Plc Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Has Received A CE Mark for Use as A Consumer Self-Test in the UK and EU

Avacta Group Plc Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

Avacta Group plc Announces US Food and Drug Administration Approval of IND Application for AVA6000

First half 2021 earnings released: UK£0.041 loss per share (vs UK£0.037 loss in 1H 2020)